← Back to Search

HPV Vaccine and Screening Strategy for Cervical Cancer

N/A

Recruiting

Led By Jane Montealegre, M D

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Females; Age ≥30 years

Have no history of hysterectomy with removal of the cervix

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average 1 year.

Awards & highlights

Study Summary

This trial found that HPV vaccine and cervical screening can help prevent cervical cancer.

Who is the study for?

This trial is for women aged 30 or older living in RGV who haven't had a Pap test in the last 3.5 years or a Pap/HPV co-test in the past 5.5 years, and have not been diagnosed with cervical cancer or severe cervical dysplasia. Participants must be able to understand English or Spanish, are not pregnant, and do not belong to vulnerable populations.Check my eligibility

What is being tested?

The study tests a community-based strategy called PRECEDE-PROCEED aimed at improving access to cervical cancer screening for early detection of potential disease caused by HPV.See study design

What are the potential side effects?

Since this trial focuses on a public health intervention rather than medication, it does not involve typical drug side effects. However, participants may experience discomfort during screening procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman aged 30 or older.

Select...

I have not had a hysterectomy that removed my cervix.

Select...

I have never had cervical cancer or severe abnormal cell changes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average 1 year.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average 1 year.

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Design

1Treatment groups

Experimental Treatment

Group I: PRECEDE-PROCEEDExperimental Treatment1 Intervention

To identify predisposing, enabling, and reinforcing factors that could influence women's decision to participate in self-sample HPV testing and diagnostic follow-up.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,788,554 Total Patients Enrolled

Jane Montealegre, M DPrincipal InvestigatorM.D. Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being treated in this experiment?

"Affirmative. Clinicaltrials.gov attests to this trial's active recruitment status, which was first published on October 30th 2023 and has been recently modified the same day. This clinical study is currently enrolling 920 patients at a single research centre."

Answered by AI

Is this research endeavor actively seeking participants?

"Yes, clinicaltrials.gov currently lists the trial as actively recruiting volunteers. This research project first appeared on October 30th 2023 and has been updated since; with 920 patients sought from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

2023. "Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06109870.

All > Hpv > Cervical Cancer